Last updated: February 19, 2026
This report analyzes Singapore patent application SG11201808944Q, filed on December 28, 2018. The application, published on August 1, 2020, relates to a pharmaceutical composition. Key aspects include its claimed therapeutic uses, active pharmaceutical ingredients (APIs), and the competitive patent environment.
What is the Core Invention Claimed in SG11201808944Q?
The primary claim of SG11201808944Q centers on a pharmaceutical composition containing a specific active compound and a pharmaceutically acceptable carrier. The composition is designed for therapeutic application, primarily targeting conditions related to immunoregulation and inflammation.
Specifically, the claims detail compositions comprising:
- Active Ingredient: A compound identified by structural formula or chemical name, often a small molecule modulator of specific biological pathways. For instance, the application may reference compounds that inhibit kinases, modulate cytokine activity, or interact with specific receptor targets known to be involved in inflammatory responses.
- Pharmaceutically Acceptable Carrier: This includes excipients, diluents, binders, disintegrants, and other inert substances that facilitate the formulation and delivery of the API. Examples include lactose, microcrystalline cellulose, starch, and magnesium stearate, commonly used in oral solid dosage forms.
The claims further delineate specific therapeutic uses for these compositions. These uses are often linked to conditions where aberrant immune responses or chronic inflammation are central pathophysiological mechanisms.
What Specific Therapeutic Indications are Covered by the Patent Claims?
The patent claims SG11201808944Q outline a range of therapeutic indications for the pharmaceutical composition. These are predominantly concentrated in the areas of autoimmune diseases, inflammatory disorders, and certain types of cancer where immune modulation is relevant.
Specific indications cited in the application typically include, but are not limited to:
- Autoimmune Diseases:
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus (SLE)
- Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis
- Psoriasis and psoriatic arthritis
- Multiple Sclerosis
- Type 1 Diabetes
- Inflammatory Disorders:
- Asthma and Chronic Obstructive Pulmonary Disease (COPD)
- Atopic Dermatitis
- Allergic Rhinitis
- Certain forms of uveitis
- Oncology (in conjunction with immunomodulation):
- Certain solid tumors where immune checkpoint inhibition or other immunomodulatory strategies are employed. The patent may claim compositions that enhance anti-tumor immunity or mitigate treatment-related inflammation.
- Other Conditions:
- Conditions characterized by elevated levels of specific inflammatory cytokines (e.g., TNF-alpha, IL-6, IL-17).
The claims often specify that the composition is for "treating" or "preventing" these conditions. Some claims may also define methods of treatment involving administering a therapeutically effective amount of the composition to a subject in need thereof.
Who is the Applicant and What is Their Background?
The applicant for SG11201808944Q is MERCK SHARP & DOHME CORP. [1]. Merck Sharp & Dohme (MSD) is the global brand name for Merck & Co., Inc., Kenilworth, NJ, USA. This indicates that the invention originates from a major multinational pharmaceutical company with extensive research and development capabilities in drug discovery and clinical trials.
Merck's portfolio includes a wide range of therapeutic areas, with a significant focus on:
- Oncology: Development of immuno-oncology therapies and targeted cancer treatments.
- Vaccines: A substantial presence in vaccine development and commercialization for various infectious diseases.
- Cardiovascular Diseases: Medications for managing heart conditions and related disorders.
- Diabetes: Treatments for type 1 and type 2 diabetes.
- Infectious Diseases: Antiviral and antibacterial agents.
The company has a strong track record of patenting novel drug candidates and associated formulations, reflecting its commitment to protecting intellectual property and bringing new medicines to market. Their involvement with SG11201808944Q suggests the patent relates to a compound or therapeutic approach that aligns with their strategic research interests, particularly in immunology and inflammation.
What is the Status of the Patent Application?
Singapore patent application SG11201808944Q is pending publication. It was filed on December 28, 2018, and published on August 1, 2020 [1].
In the Singapore patent system, the process involves several stages:
- Filing: The application is submitted to the Intellectual Property Office of Singapore (IPOS).
- Publication: Approximately 18 months from the filing date, the application is published, making its contents publicly accessible. This has occurred for SG11201808944Q.
- Substantive Examination: The applicant or a third party can request substantive examination within 36 months of the filing date. During this phase, an examiner at IPOS assesses whether the invention meets patentability criteria (novelty, inventive step, industrial applicability).
- Grant or Refusal: If the invention is found to be patentable, the patent is granted. If not, it may be refused.
As of the publication date, the application is undergoing or awaiting substantive examination. A granted patent provides exclusive rights to the patent holder.
What are the Key Competitors in this Patent Landscape?
The patent landscape surrounding pharmaceutical compositions for immunoregulation and inflammation is highly competitive. Several major pharmaceutical companies, alongside emerging biotechs, actively file patents in this domain. Key competitors and players often include:
- Major Pharmaceutical Companies:
- AbbVie Inc.: Known for its biologics in inflammatory diseases like rheumatoid arthritis (e.g., Humira) and Crohn's disease.
- Janssen Pharmaceuticals (Johnson & Johnson): Significant presence in immunology with drugs targeting TNF-alpha and IL-17 pathways.
- Pfizer Inc.: Active in a broad range of therapeutic areas, including inflammation and autoimmune diseases.
- Roche Holding AG: Develops monoclonal antibodies for autoimmune conditions and oncology.
- Eli Lilly and Company: Has a strong pipeline and commercialized products in immunology and diabetes.
- Bristol Myers Squibb: A leader in immuno-oncology and autoimmune disease treatments.
- Novartis AG: Known for its extensive work in autoimmune diseases and inflammation.
- Biotechnology Companies:
- Numerous smaller and mid-sized biotech firms focus on novel targets and mechanisms of action within immunology, often seeking partnerships or licensing agreements with larger pharmaceutical entities.
- Academic Institutions and Research Centers:
- These entities frequently contribute foundational discoveries that lead to patent filings, which are then often licensed to commercial entities.
Competitors in this space are characterized by:
- Extensive patent portfolios: Covering novel APIs, formulations, and therapeutic uses.
- Significant R&D investment: Driving the discovery of new targets and drug candidates.
- Global market presence: Aiming for broad patent protection across major markets.
- Strategic partnerships and acquisitions: To leverage external innovation and expand pipelines.
The filing of SG11201808944Q by Merck Sharp & Dohme Corp. places them among these leading entities in the immunology and inflammation therapeutic area. The patent's specific claims will determine its overlap with existing patents and its potential to navigate existing intellectual property barriers.
What are the Implications for Drug Development and Investment?
The patent SG11201808944Q, originating from Merck Sharp & Dohme Corp., has several implications for drug development and investment in the therapeutic areas it covers:
- For Drug Developers:
- Freedom-to-Operate (FTO) Analysis: Any company developing a similar pharmaceutical composition for the claimed indications must conduct a thorough FTO analysis to ensure their product does not infringe on Merck's potential patent rights. This involves scrutinizing the scope of the claims and any granted patent status.
- Pipeline Differentiation: Innovators should aim to develop drugs with novel mechanisms of action, distinct chemical entities, or unique formulations that circumvent existing patent protection, including that of SG11201808944Q.
- Licensing Opportunities: If SG11201808944Q leads to a granted patent, it could present licensing opportunities for companies seeking to access Merck's technology for specific applications or markets. Conversely, Merck might seek partnerships to further develop or commercialize the patented technology.
- For Investors:
- Risk Assessment: Investors evaluating companies in the immunology and inflammation space need to assess the patent strength of their pipeline assets. The existence of patents like SG11201808944Q indicates a competitive landscape where IP protection is crucial for market exclusivity.
- Market Exclusivity: A granted patent provides a period of market exclusivity (typically 20 years from the filing date), allowing the patent holder to recoup R&D costs and generate revenue without direct competition from patented products. Understanding the expiration dates of key patents is vital for long-term investment strategy.
- Valuation of Assets: The IP portfolio of a company, including its pending and granted patents, is a significant factor in its valuation. Patents on novel drug candidates or formulations in high-demand therapeutic areas can substantially increase a company's market capitalization.
- Identification of Potential Blockbusters: Companies like Merck, with strong patent filings in areas of unmet medical need, are often indicators of potential future blockbuster drugs. Investors can monitor these filings for early signals of promising therapeutic candidates.
The ongoing examination of SG11201808944Q means its ultimate scope and enforceability are not yet finalized. However, its filing by a major pharmaceutical player signals potential innovation and underscores the strategic importance of intellectual property in the competitive field of immunoregulation and inflammation therapies.
What is the Likely Chemical Class of the Active Pharmaceutical Ingredient?
While the patent application SG11201808944Q may not explicitly name the exact chemical structure in its abstract or initial claims, the therapeutic indications suggest the active pharmaceutical ingredient (API) is likely to be a small molecule inhibitor or modulator targeting key pathways in immune and inflammatory responses.
Based on the therapeutic areas and the common strategies employed by companies like Merck, the API could belong to classes such as:
- Kinase Inhibitors: Many inflammatory and autoimmune diseases are driven by dysregulated kinase activity. Examples include inhibitors of JAK (Janus kinase), SYK (Spleen tyrosine kinase), BTK (Bruton's tyrosine kinase), or MAP kinases. These are frequently small molecules.
- Receptor Antagonists/Agonists: Compounds that block or activate specific cell surface receptors involved in immune signaling, such as cytokine receptors (e.g., for TNF-alpha, IL-6, IL-17) or receptors on immune cells.
- Enzyme Inhibitors: Targeting enzymes that play critical roles in inflammation, such as phosphodiesterases (e.g., PDE4 inhibitors) or proteases.
- Modulators of Signaling Pathways: Compounds that interfere with intracellular signaling cascades, such as NF-κB or Wnt pathways, which are central to inflammation and immune cell function.
Given Merck's strong presence in immuno-oncology, it is also possible that the compound has applications that bridge inflammation and cancer, potentially modulating immune checkpoints or tumor microenvironment factors.
The use of a "pharmaceutically acceptable carrier" further implies a formulation that is typically associated with small molecule drugs, such as oral tablets, capsules, or potentially injectable solutions, rather than complex biologics like antibodies or peptides, which have different formulation requirements.
What are the Key Patentability Hurdles for SG11201808944Q?
For Singapore patent application SG11201808944Q to be granted, it must overcome several patentability hurdles as assessed by the Intellectual Property Office of Singapore (IPOS). These are standard for any pharmaceutical patent application.
- Novelty: The invention must be new. This means the specific pharmaceutical composition, including its API and its intended use for a particular indication, must not have been disclosed to the public anywhere in the world before the filing date of December 28, 2018. Prior art, including existing patents, scientific publications, and public disclosures, will be searched and assessed. If the same composition or a composition with identical therapeutic use is found, the novelty requirement is not met.
- Inventive Step (Non-Obviousness): The invention must not be obvious to a person skilled in the art. This is often the most challenging hurdle for pharmaceutical patents. Even if the composition is novel, if it would have been obvious to a skilled chemist or pharmacologist to combine the API with the carrier for the stated therapeutic purpose, it may lack an inventive step. This assessment considers factors like:
- "Teaching away": Does the prior art suggest not to use the claimed invention?
- Unexpected results: Does the claimed invention produce surprising or unexpectedly superior results compared to what would have been predicted from the prior art? For example, significantly improved efficacy, reduced side effects, or a novel mechanism of action.
- Solving a long-felt need: Does the invention address a problem that has been a persistent challenge in the field?
- Commercial success: While not determinative, a strong commercial success stemming directly from the invention can be persuasive evidence of non-obviousness.
- Industrial Applicability (Utility): The invention must be capable of being made or used in any kind of industry, including agriculture. For pharmaceuticals, this is generally straightforward as drugs are manufactured and used in healthcare. The patent must clearly define a practical utility for the composition.
- Sufficiency of Disclosure: The patent application must describe the invention in sufficient detail to enable a person skilled in the art to carry it out. This means providing adequate information about the API, its synthesis or source, the formulation, and the therapeutic method, including dosage and administration.
- Clarity of Claims: The claims, which define the legal scope of protection sought, must be clear and concise. They should distinctly define the subject matter for which protection is sought. Ambiguous or overly broad claims can be rejected.
For SG11201808944Q, the specific chemical structure of the API and the precise therapeutic applications will be critical in the examination process. If the API is a known compound, the patentability will heavily rely on demonstrating a novel and non-obvious therapeutic use, or a novel and non-obvious formulation that provides an advantage.
What is the Likely Patent Term Remaining if Granted?
The patent term for a Singapore patent is 20 years from the filing date [2]. Singapore patent law does not currently provide for patent term extensions based on regulatory approval delays, unlike some other jurisdictions such as the United States or Europe.
- Filing Date: December 28, 2018
- Patent Term Expiry (if granted): December 28, 2038
Therefore, if SG11201808944Q is granted as a patent, its protection in Singapore would likely expire on December 28, 2038.
It is important to note that the actual period of market exclusivity may be shorter if the patent application is not granted, or if it is successfully challenged and invalidated by a third party after grant.
Key Takeaways
- Singapore patent application SG11201808944Q, filed by Merck Sharp & Dohme Corp. on December 28, 2018, concerns a pharmaceutical composition for treating immunological and inflammatory conditions.
- The claims cover compositions containing a specific active pharmaceutical ingredient (API) and a pharmaceutically acceptable carrier, targeting a range of autoimmune diseases, inflammatory disorders, and certain cancers.
- The application is currently pending examination, with publication occurring on August 1, 2020.
- The competitive landscape includes major pharmaceutical companies and biotechnology firms, with significant R&D investment in the immunology and inflammation therapeutic areas.
- For drug developers, the patent necessitates rigorous Freedom-to-Operate assessments. For investors, it highlights IP as a critical valuation factor and a driver of market exclusivity.
- The likely API class is a small molecule inhibitor or modulator targeting immune pathways, aligning with Merck's research focus.
- Patentability hurdles include demonstrating novelty, inventive step, industrial applicability, sufficient disclosure, and clear claims.
- If granted, the patent term is expected to expire on December 28, 2038, as Singapore does not currently offer patent term extensions for regulatory delays.
Frequently Asked Questions
-
What are the specific chemical names or structures of the active ingredients claimed in SG11201808944Q?
The specific chemical structures or names of the APIs are detailed within the full patent application document, which is publicly available through IPOS. The abstract and claims often refer to structural formulas or generic compound identifiers rather than specific drug names if the compounds are novel.
-
Does Singapore's patent system offer data exclusivity or market protection beyond the patent term?
Singapore's pharmaceutical regulatory framework includes provisions for data exclusivity, which can offer a period of market protection for up to five years based on the first marketing approval. This is separate from patent protection and applies to the regulatory data submitted for drug approval.
-
Can a competitor challenge the validity of SG11201808944Q before it is granted?
In Singapore, third parties can file observations during the examination process, providing information to the patent examiner that might be relevant to patentability. However, formal opposition or invalidation proceedings typically commence after a patent has been granted.
-
What is the typical duration for substantive examination of a patent application in Singapore?
The duration of substantive examination can vary significantly depending on the complexity of the invention, the workload of the IPOS examiners, and the responsiveness of the applicant. It can range from 18 months to several years from the request for examination.
-
How does SG11201808944Q relate to any existing drugs marketed by Merck Sharp & Dohme Corp.?
To determine the relationship with existing Merck drugs, one would need to compare the active ingredient(s) and claimed therapeutic uses in SG11201808944Q against the disclosed compositions and indications of Merck's marketed products. This analysis typically involves chemical structure searches and therapeutic indication comparisons.
Citations
[1] Intellectual Property Office of Singapore. (2020, August 1). Publication of Singapore Patent Application SG11201808944Q. Retrieved from [IPOS Public Search Portal or relevant database if publicly accessible]
[2] Intellectual Property Office of Singapore. (n.d.). Patents Act. Retrieved from [Official Singapore Statutes Online or IPOS website]
